Andyforce Begins Production of COVID-19 Rapid Diagnostic Kits

[Asia Economy Reporter Jang Hyowon] AndyForce announced on the 26th that its subsidiary CureBio is preparing to produce immune antibody response diagnostic kits for rapid diagnosis of COVID-19 and reverse transcription polymerase chain reaction (PCR) reagents at its own KGMP factory capable of manufacturing reagents for in vitro diagnostic medical devices.

Currently, CureBio's Absogen kits, developed and manufactured at its own factory certified for Good Manufacturing Practice (GMP) for medical devices, are kits that can rapidly diagnose pneumonia and sepsis. After signing a supply contract with Anguk Bio Diagnostics, they are jointly selling to domestic university hospitals.

CureBio already possesses its own diagnostic kit pipeline capable of rapid and accurate diagnosis of pneumonia and sepsis. Utilizing this, they have completed preparations to produce immune diagnostic kits that qualitatively detect three target genes of the coronavirus and reagents for reverse transcription polymerase chain reaction (Real-Time PCR), a type of comprehensive viral molecular diagnosis.

A company official stated, “We received requests from domestic and international companies to develop rapid COVID-19 diagnostic kits and have been swiftly preparing since February. We have completed internal optimization tests for diagnosis and started production. We are concurrently proceeding with domestic certification and European certification (CE-IVD), so we expect to complete certification soon and begin supply.”